Minnesota Oncology

Colon Cancer News

TAS-102 Improves Survival in Advanced Colorectal Cancer (July 9, 2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

More Effective Colorectal Cancer Prevention with Colonoscopy Doctor with High Rate of Polyp Detection (July 3, 2014)

Recent findings suggest that for more effective colorectal cancer prevention, it’s best to choose a physician for colonoscopy with a higher rate of precancerous polyp detection; meaning that he or she detects more polyps than colleagues in proportion... Continue Reading

Study Shows Polypectomy as Effective as Partial Colon Resection (July 2, 2014)

A team from Stony Brook University reported that patients requiring removal of colon polyps could be effectively treated with laparoscopic-assisted polypectomy (LACP) and that the procedure required fewer resources than did partial colon resection (laparoscopic... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Oncotype DX Changes Treatment Recommendations in Stage II Colon Cancer (December 26, 2013)

Use of the Oncotype DX® colon cancer test changed treatment recommendations in 29 percent of stage II colon cancer patients, according to the results of a study published in Current Medical Research and Opinion. Stage II colon cancer refers to cancer... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Latest Colon Cancer News By Stage


Adjuvant (I-III, A-C) Colon Cancer

Study Shows Polypectomy as Effective as Partial Colon Resection (July 2, 2014)

A team from Stony Brook University reported that patients requiring removal of colon polyps could be effectively treated with laparoscopic-assisted polypectomy (LACP) and that the procedure required fewer resources than did partial colon resection (laparoscopic... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Oncotype DX Changes Treatment Recommendations in Stage II Colon Cancer (December 26, 2013)

Use of the Oncotype DX® colon cancer test changed treatment recommendations in 29 percent of stage II colon cancer patients, according to the results of a study published in Current Medical Research and Opinion. Stage II colon cancer refers to cancer... Continue Reading

Genomic Testing May Reduce Medical Costs for Colon Cancer (June 14, 2013)

Use of the Oncotype DX® colon cancer test to guide treatment decisions may reduce medical costs and improve patient well-being. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The Oncotype... Continue Reading

Second Large Study Confirms Oncotype DX Can Predict Recurrence in Stage 2 Colon Cancer (April 22, 2013)

Results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test confirm that Recurrence Score® (RS) results improve the ability to differentiate high recurrence risk disease from low recurrence risk disease, beyond... Continue Reading

More Adjuvant (I-III, A-C) Colon Cancer

Screening/Prevention Colon Cancer

More Effective Colorectal Cancer Prevention with Colonoscopy Doctor with High Rate of Polyp Detection (July 3, 2014)

Recent findings suggest that for more effective colorectal cancer prevention, it’s best to choose a physician for colonoscopy with a higher rate of precancerous polyp detection; meaning that he or she detects more polyps than colleagues in proportion... Continue Reading

Study Shows Polypectomy as Effective as Partial Colon Resection (July 2, 2014)

A team from Stony Brook University reported that patients requiring removal of colon polyps could be effectively treated with laparoscopic-assisted polypectomy (LACP) and that the procedure required fewer resources than did partial colon resection (laparoscopic... Continue Reading

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Colorectal Cancer Screening Works Over Long-Term (October 4, 2013)

The results of a study published in the New England Journal of Medicine, suggest that it pays to follow colorectal cancer screening recommendations—and people who do follow the guidelines are less likely to develop colon cancer than people who do not. Colorectal... Continue Reading

More Screening/Prevention Colon Cancer

Stage IV (D)/Relapsed Colon Cancer

TAS-102 Improves Survival in Advanced Colorectal Cancer (July 9, 2014)

Researchers recently reported that the new combination agent TAS-102 improves overall survival in patients whose metastatic colorectal cancer is refractory to standard therapies. These results were recently reported at the ESMO 16th World Congress on... Continue Reading

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer (June 20, 2014)

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX or... Continue Reading

Predicting SIR-Spheres® microspheres Treatment Outcomes for Metastatic Colorectal Cancer (March 5, 2014)

Pre-treatment laboratory tests may play a key role in predicting patient outcomes prior to selective internal radiation therapy for metastatic colorectal cancer, while a new modeling technology for enhancing delivery of treatment could improve treatment... Continue Reading

Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium (February 7, 2014)

New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test REDWOOD CITY, Calif., Jan. 29, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results from the Oncotype... Continue Reading

Erbitux Plus Chemo Boosts Survival in Patients with Colorectal Cancer and Liver Metastases (May 29, 2013)

Adding Erbitux® (cetuximab) to standard chemotherapy might allow some patients with colorectal cancer and inoperable liver metastases to undergo successful surgical resection of the liver metastasis, according to the results of a study published in the Journal... Continue Reading

More Stage IV (D)/Relapsed Colon Cancer